General election of trade unions of pharmaceutical companies
Release time:
2020-12-11
Pharmaceutical Company Trade Union General Election
On December 4, Jinhua Pharmaceutical Company held a staff (member) congress to elect a new trade union committee. Fan Tufa, member of the general Party branch of the pharmaceutical company, made a trade union work report entitled "cohesion, building harmony, and striving for the sustained and stable development of the company" on behalf of the last trade union. He said that under the leadership of the higher-level trade union and the general party branch of the pharmaceutical company, with the joint efforts of all employees, the work level of the trade union has been continuously improved and the immediate interests of the employees have been safeguarded. Looking back on the past, the trade union of the pharmaceutical company has always focused on the work of the enterprise center, cooperated with the arrangement of the general party branch, regarded serving employees as the focus of daily work, actively organized various activities, cared about the lives of employees, did practical things for employees, and contributed to the stable development of the pharmaceutical company. Made a positive contribution. The report also puts forward the working ideas and specific work of the trade union of pharmaceutical companies in the next few years.
A total of 35 representatives of employees (members) attended the meeting. According to the relevant provisions of the Regulations on the Election of Primary Organizations of Trade Unions, secret ballot elections were conducted. The 8th Trade Union Committee composed of Fan Tufa, Hu Xuechun, Qian Weiling, Ni Zhiquan and Wang Ximing and the 8th Trade Union Funds Review Committee composed of Sun Zhiru, Wang Ximing and Xiao Jiamin were elected. Wu Weisheng, secretary of the general party branch and general manager of the pharmaceutical company, put forward requirements for the new trade union committee, hoping that under the current new situation of the development of the pharmaceutical circulation industry, they will improve their own quality, base themselves on their posts, take the initiative to act, improve their work ability and level, improve the cohesion and influence of trade union organizations, and make greater efforts for the stable development of pharmaceutical companies.
Jin Huazhong, Secretary of the Party Committee and Chairman of the Trade Union of Pharmaceutical Company, attended the meeting. He asked the new trade union committee to achieve "double love" and "double support", urge enterprises to love employees and safeguard their legitimate rights and interests, and at the same time guide employees Love the enterprise, support the enterprise, and develop together with the enterprise; improve working ability, gather employees, and build a good enterprise; carry out cultural and sports activities to promote employees' physical and mental health; strengthen their own learning, improve their own quality, set an example, enhance the cohesion of employees, and make greater achievements with the times.
After the meeting, the 8th Trade Union Committee and the Economic Review Committee held their first meeting and elected Fan Tufa as the chairman of the trade union and Sun Zhiru as the director of the Economic Review Committee. (Tang yuefen)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page